Skip to main content
. 2021 Mar 8;10:e66125. doi: 10.7554/eLife.66125

Table 2. Primary, secondary, and exploratory study outcomes.

Parallel SOC (N = 130) SOC + Anakinra after propensity matching (N = 130) OR (95% CI) p-value
Severe respiratory failure by day 14, No. (%) 77 (59.2) 29 (22.3) 0.19 (0.12–0.34) <0.0001
Mechanical ventilation (MV) by day 14, No. (%) 65 (50.0) 25 (19.2) 0.24 (0.14–0.42) <0.0001
Non-invasive MV by day 14, No. (%) 9 (6.9) 6 (4.6) 0.65 (0.23–1.88) 0.596
14-day mortality, No. (%) 16 (12.3) 6 (4.6) 0.35 (0.13–0.91) 0.043
SOFA score on day 7, median (Q1–Q3) 2 (0 to 3) 1 (0 to 3) NA 0.540
SOFA score on day 14, median (Q1–Q3) 2 (0–9) 1 (0–3) NA 0.191
Absolute change of SOFA score by day 7 compared to baseline, median (Q1–Q3) 0 (−1 to 1) 0 (−1 to 0) NA 0.356
Absolute change of SOFA score by day 14 compared to baseline, median (Q1–Q3) 0 (−1 to 6) −2 (−1 to 0) NA 0.004
Absolute change of respiratory symptoms score by day 7 compared to baseline, median (Q1–Q3) 0 (0 to 0.75) −1 (−3 to 0) NA 0.019
Absolute change of respiratory symptoms score by day 14 compared to baseline, median (Q1–Q3) 0 (−0.75 to 0) −2 (−4 to −1) NA 0.016
Ventilator-free days, mean (SD) 18 (11) 25 (8) NA <0.0001
30-day mortality, No. (%) 29 (22.3) 15 (11.5) 0.45 (0.23–0.90) 0.031
90-day mortality, No. (%) 40 (30.8) 22 (16.9) 0.46 (0.25–0.83) 0.013

Abbreviations: CI: confidence interval; n: number; NA: non-applicable; OR: odds ratio; Q: quartile; SD: standard deviation; SOC; standard-of-care; SOFA: sequential organ failure assessment.